CL2020002087A1 - Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b. - Google Patents

Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b.

Info

Publication number
CL2020002087A1
CL2020002087A1 CL2020002087A CL2020002087A CL2020002087A1 CL 2020002087 A1 CL2020002087 A1 CL 2020002087A1 CL 2020002087 A CL2020002087 A CL 2020002087A CL 2020002087 A CL2020002087 A CL 2020002087A CL 2020002087 A1 CL2020002087 A1 CL 2020002087A1
Authority
CL
Chile
Prior art keywords
pyridin
fluoro
cell lymphoma
methylsulfonimidoyl
methoxyphenyl
Prior art date
Application number
CL2020002087A
Other languages
English (en)
Inventor
Arne Scholz
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of CL2020002087A1 publication Critical patent/CL2020002087A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de 5-Fluoro-4-(4-fluoro-2-metoxifenil)-N-{4-[(S-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina (compuesto A), más específicamente (+)5-Fluoro-4-(4-fluoro-2-metoxifenil)-N-{4-[(S-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina (compuesto A´), para el tratamiento del linfoma difuso de células grandes B (LDCGB), especialmente en el tipo de células B del centro germinal del linfoma difuso de células grandes B y especialmente en el linfoma difuso de células grandes B cuyas células tienen una amplificación o translocación del gen MYC y/o del gen BCL2 y/o una sobreexpresión de MYC y/o BCL2.
CL2020002087A 2018-02-13 2020-08-12 Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b. CL2020002087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18156576 2018-02-13

Publications (1)

Publication Number Publication Date
CL2020002087A1 true CL2020002087A1 (es) 2020-12-11

Family

ID=61223765

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002087A CL2020002087A1 (es) 2018-02-13 2020-08-12 Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de células grandes b.

Country Status (16)

Country Link
US (1) US11701347B2 (es)
EP (1) EP3752487A1 (es)
JP (1) JP7280286B2 (es)
KR (1) KR102764122B1 (es)
CN (1) CN111727183B (es)
AU (1) AU2019221019B2 (es)
BR (1) BR112020016389A2 (es)
CA (1) CA3090843A1 (es)
CL (1) CL2020002087A1 (es)
EA (1) EA202091894A1 (es)
IL (1) IL276437B2 (es)
JO (1) JOP20200196A1 (es)
MA (1) MA51820A (es)
MX (1) MX2020008447A (es)
SG (1) SG11202006470RA (es)
WO (1) WO2019158517A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2003037346A1 (en) 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7465805B2 (en) 2004-10-05 2008-12-16 Syngenta Limited Isoxazoline derivatives and their use as herbicides
US20090099160A1 (en) 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
DE102005062742A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
JP4305477B2 (ja) 2006-07-25 2009-07-29 トヨタ自動車株式会社 火花点火式内燃機関
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
EP2094681A1 (en) 2006-12-22 2009-09-02 Novartis AG Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
KR20120049940A (ko) 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
KR20120114224A (ko) 2009-10-12 2012-10-16 마이렉시스 인코포레이티드 Ikk 엡실론 및/또는 tbk1의 억제제로서의 아미노-피리미딘 화합물
CA2789200C (en) 2010-03-22 2020-05-26 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
CA2816679A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101062A1 (en) 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
JP5947818B2 (ja) 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
KR20140048873A (ko) 2011-04-12 2014-04-24 알츠하이머즈 인스티튜트 오브 아메리카, 인크. Ikk-관련 키나제 엡실론 및 tank 결합 키나제 1 억제제의 조성물 및 치료학적 용도
CN102731413A (zh) 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
AU2012244745A1 (en) 2011-04-19 2013-09-19 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
CN103917527B (zh) 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
WO2014076028A1 (en) 2012-11-15 2014-05-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
ME02880B (me) * 2012-11-15 2018-04-20 Bayer Pharma AG Derivati 5-fluoro- n- (piridin -2-il}piridi n- 2 - amina koji sadrze sulfoksiminsku grupu
EP3016945B1 (en) 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
JP2018509440A (ja) * 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト リンパ腫の治療のための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma

Also Published As

Publication number Publication date
JOP20200196A1 (ar) 2020-08-13
KR102764122B1 (ko) 2025-02-05
EA202091894A1 (ru) 2020-12-28
US20210015806A1 (en) 2021-01-21
AU2019221019B2 (en) 2024-05-02
BR112020016389A2 (pt) 2020-12-15
IL276437B2 (en) 2024-03-01
US11701347B2 (en) 2023-07-18
JP2021514386A (ja) 2021-06-10
MX2020008447A (es) 2020-09-28
CA3090843A1 (en) 2019-08-22
IL276437A (en) 2020-09-30
JP7280286B2 (ja) 2023-05-23
SG11202006470RA (en) 2020-08-28
WO2019158517A1 (en) 2019-08-22
KR20200119800A (ko) 2020-10-20
MA51820A (fr) 2021-05-19
IL276437B1 (en) 2023-11-01
AU2019221019A1 (en) 2020-07-23
CN111727183A (zh) 2020-09-29
EP3752487A1 (en) 2020-12-23
CN111727183B (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2020004541A (es) Edicion de genes de celulas primarias.
MX2022004080A (es) Receptor de antígeno quimérico potenciado para la modificación de células efectoras inmunitarias y uso del mismo.
MX2022000553A (es) Modificación de células efectoras inmunitarias y uso de las mismas.
MX2023002195A (es) Compuestos y metodos para el tratamiento de infecciones virales.
MX2020005477A (es) Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
EA202191559A1 (ru) Модифицированные аминовые липиды
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
MX2020012295A (es) Composiciones de fusosoma y usos de estas.
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
MX2022006444A (es) Linfocitos t activados por bite ex vivo.
MX385562B (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
MX2020003954A (es) Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
GB2533063A (en) Structures and methods with reduced sensitivity to surface charge
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
BR112014017840A8 (pt) Compostos terapeuticamente ativos, sua composição farmacêutica e seu uso
ECSP15018618A (es) Inhibidores no nucleósidos de la transcriptasa inversa
AR111360A1 (es) Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
MX2012008717A (es) Composiciones para el cuidado oral.
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
MX2018012945A (es) Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.